Fascin expression in low-grade uterine endometrioid adenocarcinoma: Correlation with microcystic, elongated and fragmented (MELF)-type alteration at the deep invasive margin

Histopathology

Volumn 59, Issue 1, 2011, Pages 73-80

  Stewart, Colin J R ^a   Crook, Maxine L ^a   Manso, Lorella ^b  

^a KING EDWARD MEMORIAL HOSPITAL   (Australia)

^b FREMANTLE HOSPITAL   (Australia)

Author keywords

Carcinoma; Endometrium; Fascin; Invasion; MELF

Indexed keywords

CYTOKERATIN 7; FASCIN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER STAGING; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; EPITHELIUM CELL; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LOW GRADE UTERINE ENDOMETRIOID ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STROMA CELL;

AGED; AGED, 80 AND OVER; CARCINOMA, ENDOMETRIOID; CARRIER PROTEINS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-7; MICROFILAMENT PROTEINS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS;

EID: 79960467412     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.03893.x     Document Type: Article

References (47)

1. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet 2005; 366; 491-505.
2. Sorosky JI. Endometrial cancer. Obstet. Gynecol. 2008; 111; 436-447.
3. Prat J. Prognostic parameters of endometrial carcinoma. Hum. Pathol. 2004; 35; 649-662.
4. Mannelqvist M, Stefansson I, Salvesen HB, Akslen LA. Importance of tumour cell invasion in blood and lymphatic vasculature among patients with endometrial carcinoma. Histopathology 2009; 54; 174-183.
5. Moberger B, Auer G, Einhorn N, Moberger G. The prognostic significance of growth pattern and its relation to tumor cell nuclear DNA content in endometrial carcinoma. Acta Oncol. 1990; 29; 17-23.
6. Lee KR, Vacek PM, Belinson JL. Traditional and nontraditional histopathologic predictors of recurrence in uterine endometrioid adenocarcinoma. Gynecol. Oncol. 1994; 54; 10-18.
7. Mittal KR, Barwick KW. Diffusely infiltrating adenocarcinoma of the endometrium. A subtype with poor prognosis. Am. J. Surg. Pathol. 1988; 12; 754-758.
8. Landry D, Mai KT, Senterman MK et al. Endometrioid adenocarcinoma of the uterus with a minimal deviation invasive pattern. Histopathology 2003; 42; 77-82.
9. Ambros RA, Ballouk F, Malfetano JH, Ross JS. Significance of papillary (villoglandular) differentiation in endometrioid carcinoma of the uterus. Am. J. Surg. Pathol. 1994; 18; 569-575.
10. Stewart CJR, Amanuel B, Grieu F, Carrello A, Iacopetta B. KRAS mutation and microsatellite instability in endometrial adenocarcinomas showing MELF-type myometrial invasion. J. Clin. Pathol. 2010; 63; 604-608.
11. Murray SK, Young RH, Scully RE. Unusual epithelial and stromal changes in myoinvasive endometrioid adenocarcinomas: a study of their frequency, associated diagnostic problems, and prognostic significance. Int. J. Gynecol. Pathol. 2003; 22; 324-333.
12. Stewart CJR, Brennan BA, Leung YC, Little L. MELF pattern invasion in endometrial carcinoma: association with low-grade, myoinvasive endometrioid tumours, focal mucinous differentiation and vascular invasion. Pathology 2009; 41; 471-476.
13. Pavlakis K, Messini I, Panoskaltsis T et al. MELF invasion in endometrial cancer as a risk factor for lymph node metastasis. Histopathology 2011; 58; 966-973.
14. McKenney JK, Kong CS, Longacre TA. Endometrial adenocarcinoma associated with subtle lymph-vascular space invasion and lymph node metastasis: a histologic pattern mimicking intravascular and sinusoidal histiocytes. Int. J. Gynecol. Pathol. 2005; 24; 73-78.
15. Stewart CJR, Crook ML, Leung YC, Platten M. Expression of cell cycle regulatory proteins in endometrial adenocarcinoma: variations in conventional tumor areas and in microcystic, elongated and fragmented glands. Mod. Pathol. 2009; 22; 725-733.
16. Stewart CJR, Little L. Immunophenotypic features of MELF pattern invasion in endometrial adenocarcinoma: evidence for epithelial-mesenchymal transition. Histopathology 2009; 55; 91-101.
17. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006; 127; 679-695.
18. Hu M, Polyak K. Microenvironmental regulation of cancer development. Curr. Opin. Genet. Dev. 2008; 18; 27-34.
19. Stewart CJR, Crook ML. Galectin-3 expression in uterine endometrioid adenocarcinoma; comparison of staining in conventional tumor glands and in areas of MELF pattern myometrial invasion. Int. J. Gynecol. Pathol. 2010; 29; 555-561.
20. Adams JC. Roles of fascin in cell adhesion and motility. Curr. Opin. Cell Biol. 2004; 16; 590-596.
21. Hashimoto Y, Skacel M, Adams JC. Roles of fascin in human carcinoma motility and signaling: prospects for a novel biomarker? Int. J. Biochem. Cell Biol. 2005; 37; 1787-1804.
22. Grothey A, Hashizume R, Sahin AA, McCrea PD. Fascin, an actin-bundling protein associated with cell motility, is upregulated in hormone receptor negative breast cancer. Br. J. Cancer 2000; 83; 870-873.
23. Pelosi G, Pastorino U, Pasini F et al. Independent prognostic value of fascin immunoreactivity in stage 1 nonsmall cell lung cancer. Br. J. Cancer 2003; 88; 537-547.
24. Hashimoto Y, Shimada Y, Kawamura J, Yamasaki S, Imamura M. The prognostic relevance of fascin expression in human gastric carcinoma. Oncology 2004; 67; 262-270.
25. Hashimoto Y, Ito T, Okumura T et al. Prognostic significance of fscin overexpression in human esophageal squamous cell carcinoma. Clin. Cancer Res. 2005; 11; 2597-2605.
26. Vignjevic D, Schoumacher M, Gavert N et al. Fascin, a novel target of β-catenin-TCF signalling, is expressed at the invasive front of human colon cancer. Cancer Res. 2007; 67; 6844-6853.
27. Won KY, Kim GY, Lim SJ, Park YK, Kim YW. Prognostic significance of fascin expression in extrahepatic bile duct carcinomas. Pathol. Res. Pract. 2009; 205; 742-748.
28. Kabukcuoglu S, Oner U, Ozalp SS, Dundar E, Yalcin OT, Colak E. Prognostic significance of fascin expression in endometrioid carcinoma. Eur. J. Gynaecol. Oncol. 2006; 27; 481-486.
29. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int. J. Gynecol. Obstet. 2009; 105; 103-104.
30. Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009; 28; 15-33.
31. Jawhari AU, Buda A, Jenkins M et al. Fascin, an actin-bundling protein, modulates colonic epithelial cell invasiveness and differentiation in vitro. Am. J. Pathol. 2003; 162; 69-80.
32. Li A, Dawson JC, Forero-Vargas M et al. The actin-bundling protein fascin stabilizes actin in invadopodia and potentiates protrusive invasion. Curr. Biol. 2010; 20; 339-345.
33. Hu W, McCrea PD, Deavers M, Kavanagh JJ, Kudelka AP, Verschraegen CF. Increased expression of fascin, motility associated protein, in cell cultures derived from ovarian cancer and in borderline and carcinomatous ovarian tumors. Clin. Exp. Metastasis 2000; 18; 83-88.
34. Kostopoulou E, Daponte A, Terzis A et al. Fascin in ovarian epithelial tumors. Histol. Histopathol. 2008; 23; 935-944.
35. Lin CK, Chao TK, Yu CP, Yu MH, Jin JS. The expression of six biomarkers in the four most common ovarian cancers: correlation with clinicopathological parameters. APMIS 2009; 117; 162-175.
36. Wen YH, Yee H, Goswami S, Shukla PS. Fascin expression in serous tumors of ovary correlates with aggressiveness of malignancy. Int. J. Gynecol. Pathol. 2009; 28; 187-192.
37. Kostopoulou E, Angelidou S, Daponte A et al. Fascin can be an auxiliary immunomarker of ovarian granulosa cell tumors: comparison with calretinin and inhibin-α. Eur. J. Gynaecol. Oncol. 2008; 29; 638-642.
38. Daponte A, Kostopoulou E, Minas M, Koukoulis G, Messinis JE. Prognostic significance of fascin expression in advanced poorly differentiated serous ovarian cancer. Anticancer Res. 2008; 28; 1905-1910.
39. Houghton O, Connolly LE, McCluggage WG. Morules in endometrioid proliferations of the uterus and ovary consistently express the intestinal transcription factor CDX2. Histopathology 2008; 53; 156-165.
40. INK4A and pRb expression during trans-differentiation of endometrial carcinoma cells. Int. J. Cancer 2006; 119; 2294-2303.
41. Chiarelli S, Buritica C, Litta P, Ciani S, Guarch R, Nogales FF. An immunohistochemical study of morules in endometrioid lesions of the female genital tract: CD10 is a characteristic marker of morular metaplasia. Clin. Cancer Res. 2006; 12; 4251-4256.
42. Lin MC, Lomo L, Baak JP et al. Squamous morules are functionally inert elements of premalignant endometrial neoplasia. Mod. Pathol. 2009; 22; 167-174.
43. Lee TK, Poon RT, Man K et al. Fascin over-expression is associated with aggressiveness of oral squamous cell carcinoma. Cancer Lett. 2007; 254; 308-315.
44. Hashimoto Y, Skacel M, Lavery IC et al. Prognostic significance of fascin expression in advanced colorectal cancer: an immunohistological study of colorectal adenomas and adenocarcinomas. BMC Cancer 2006; 6; 241.
45. Wang W, Goswami S, Sahal E, Wyckoff JB, Segall JE, Condeelis JS. Tumor cells caught in the act of invading: their strategy for enhanced cell motility. Trends Cell Biol. 2005; 15; 138-145.
46. Stewart CJR, Crook ML, Doherty DA. Micro-anatomical variation in cellular proliferation in endometrial adenocarcinoma, and inverse correlation between Ki-67 and cytokeratin 7 expression. Histopathology 2010; 57; 46-54.
47. Kabukcuoglu S, Ozalp SS, Oner U, Acikalin MF, Yalcin OT, Colak E. Fascin, an actin-bundling protein expression in cervical neoplasms. Eur. J. Gynaecol. Oncol. 2005; 26; 636-641.